Pricing Log in Create free account
Saturday 7 November 2026 Export DBVT’s income statement to Excel — free account

DBV Technologies S.A.

DBVT Healthcare Biotechnology

DBV Technologies S.A.’s revenue for fiscal 2025 (year ended December 2025) was $5.6 million, up 35.8% from fiscal 2024.

Revenue
−42.9%
EPS
+40.4%
Free cash flow
−64.9%

Quarter to September 2026, against a year earlier

10.57 0.77 +7.86%
Market cap
$615.8M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
4/9
Altman Z
1.33
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 15.49
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 1 1 — — — — — 1 — — — —
Insider Ownership 39.94%

Capital & Financial Ratios $m

Size
Market Cap 615.83
Revenue ttm 3.74
Net income ttm (207.35)
Free cash flow ttm (191.71)
Net debt Q (165.50)
Valuation
P/E 0.00
Forward P/E —
Price / sales 255.21 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 6.42 (above 6: high)
Financial health
Current ratio Q 3.24 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 95.60
Growth
Revenue growth Q −42.86% (below 0%: shrinking)
Operating income growth Q −88.63% (below 0%: shrinking)
EPS, this year −8.03% (below 0%: weak)
EPS, next year A +38.29% (at or above 15%: strong)
Revenue, next year A —
EPS, past 5 yrs —
EPS, next 5 yrs A +45.77% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 211×, against a ten-year median of 21.9×; over the ten years it ranged from −1.6× in 2024 to 282× in 2021.
P/S against its own 10 years 94.01%
10-year low 10-year high
P/B against its own 10 years 80.73%
10-year low 10-year high
EV/Sales against its own 10 years 93.09%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 141 32 194 166
Receivables — — — —
Inventory — — — —
Other 18 12 19 24
159 44 213 190
2023 2024 2025 Q'26
Payables 23 22 41 42
ST’ Debt — — — —
Other 13 8 16 16
37 31 58 59

Compound Annual Growth %

10y 5y 3y
Sales (1.93%) (12.95%) 5.18%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (7.23%) (3.86%) (4.61%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.60 Actual −0.70

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −1.30 −1.15 Beat by 0.15
Q1 FY26 −0.14 −0.56 Miss by 0.42
Q2 FY26 −0.12 −0.60 Miss by 0.48
Q3 FY26 −0.60 −0.70 Miss by 0.10
Q4 FY26 −0.75 — Reports 25 March 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.56) (0.60) (0.71) — —
’25 (1.32) (1.55) (1.20) (1.21) (5.25)
’24 (1.40) (1.70) (1.58) (1.10) (5.85)
’23 (1.10) (1.30) (0.90) (0.60) (3.80)
’22 (1.50) (1.80) (0.90) (2.30) (6.20)
’21 (2.70) (2.80) (2.20) (1.30) (8.90)
’20 (3.95) (1.81) (2.82) (3.59) (14.80)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 1 1 2 — —
’25 1 2 3 1 6
’24 1 1 1 1 4
’23 2 2 2 9 16
’22 3 2 2 (1) 5
’21 3 (1) 1 3 6
’20 5 4 4 (1) 11
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (49) (53) (51) — —
’25 (20) (34) (32) (35) (121)
’24 (35) (35) (22) (12) (104)
’23 (21) (26) (20) (14) (80)
’22 (1) (10) (20) (24) (56)
’21 (36) (30) (23) (19) (108)
’20 (50) (38) (45) (34) (166)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (49) (53) (54) — —
’25 (20) (34) (33) (36) (122)
’24 (36) (36) (23) (12) (107)
’23 (21) (26) (20) (14) (80)
’22 (2) (10) (20) (24) (56)
’21 (36) (30) (23) (19) (109)
’20 (51) (38) (45) (34) (168)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 10 13 17 15 11 6 5 16 4 6 4 (6.2%) — — — —
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 0.0 pt
EBT (127) (167) (196) (171) (160) (98) (96) (73) (114) (146) (206) +1.6%
EBT margin, % (1,260.79) (1,240.18) (1,142.33) (1,165.36) (1,415.09) (1,720.20) (1,986.04) (462.35) (2,743.03) (2,598.58) (5,518.09) (1,337.8) pt
Net income (127) (167) (196) (172) (160) (98) (96) (73) (114) (147) (207) +1.7%
Per share, $
Per share, $ Revenue 2.06 2.72 2.97 1.99 1.04 0.52 0.31 0.83 0.21 0.20 0.04 (22.7%)
Earnings (25.90) (33.70) (33.90) (23.30) (14.80) (8.90) (6.20) (3.80) (5.85) (5.25) (3.09) (16.3%)
Cash flow (13.47) (26.10) (27.89) (20.04) (15.31) (9.86) (3.60) (4.19) (5.39) (4.34) (2.09) (11.8%)
Capex (1.86) (1.72) (0.97) (0.76) (0.26) (0.03) (0.05) (0.04) (0.12) (0.02) (0.04) (39.8%)
Free cash flow (15.33) (27.82) (28.86) (20.80) (15.56) (9.88) (3.64) (4.22) (5.51) (4.36) (2.13) (13.0%)
Book value 54.95 29.66 24.76 26.10 18.99 9.04 12.56 7.37 1.41 6.05 1.65 (21.7%)
Shares, m 5 5 6 7 11 11 15 19 19 28 73 +21.4%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 0.00 0.00 0.00 0.00 25.14 30.79 47.93 11.45 14.44 94.95 255.21 22.5
P/B 0.00 0.00 0.00 0.00 1.38 1.77 1.19 1.29 2.19 3.17 6.42 1.1
EV/Sales 0.00 0.00 0.00 0.00 7.77 17.28 4.78 2.48 6.66 60.52 210.91 9.9
EV/FCF 0.00 0.49 0.32 0.39 (0.52) (0.91) (0.41) (0.48) (0.26) (2.80) (4.11) (0.4)
Cash, $m
Cash, $m Operating cash flow (66) (129) (161) (148) (166) (108) (56) (80) (104) (121) (188) +7.0%
Capex (9) (9) (6) (6) (3) 0 (1) (1) (2) (1) (3) (26.9%)
Free cash flow (75) (138) (167) (154) (168) (109) (56) (80) (107) (122) (192) +5.5%
Balance, $m
Balance, $m Working capital 269 137 120 151 155 83 194 122 13 155 131 (6.0%)
Net debt (279) (154) (143) (192) (196) (77) (209) (141) (32) (194) (165) (4.0%)
Shareholders’ equity 269 147 143 193 205 99 194 140 27 169 149 (5.0%)
Returns, %
Returns, % ROA (36.25) (64.32) (97.14) (72.49) (58.66) (46.69) (48.96) (33.87) (91.63) (98.17) (127.19) (61.9) pt
ROIC 0.00 0.00 0.00 (14,425.02) (1,025.38) (280.50) 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE (40.47) (80.34) (135.22) (102.26) (80.04) (64.19) (65.55) (43.47) (135.96) (149.83) (205.75) (109.4) pt
People
People Employees 164 244 315 311 142 92 85 104 109 125 — (3.0%)
Revenue/emp, $m 0.06 0.06 0.05 0.05 0.08 0.06 0.06 0.15 0.04 0.05 — (3.4%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 2 Nov 2026

DBV Technologies S.A. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ZVRA Zevra Therapeutics, Inc. $626.6M 9.0× 9.2× +44.86% (above 0%: growing) n/m +106.77% (above 0%: growing) 95.25% 30.67% Compare
FDMT 4D Molecular Therapeutics, Inc. $621.5M — (loss-making) — (loss-making) +25,106.67% (above 0%: growing) n/m −61.28% (below 0%: shrinking) 100.00% (2,037.16%) Compare
DBVT DBV Technologies S.A. $615.8M — (loss-making) — −42.86% (below 0%: shrinking) n/m −64.93% (below 0%: shrinking) 100.00% (4,043.75%)
CADL Candel Therapeutics, Inc. $615.2M — (loss-making) — (loss-making) 0.00% n/m −93.35% (below 0%: shrinking) 0.00% 0.00% Compare
HELP Cybin Inc. $613.0M — (loss-making) — (loss-making) — n/m −25.60% (below 0%: shrinking) 0.00% 0.00% Compare
GERN Geron Corporation $610.4M — (loss-making) — (loss-making) +27.45% (above 0%: growing) n/m +176.13% (above 0%: growing) 89.95% 9.63% Compare
DSGN Design Therapeutics, Inc. $605.2M — (loss-making) — (loss-making) — n/m −7.00% (below 0%: shrinking) 0.00% 0.00% Compare
KURA Kura Oncology, Inc. $604.9M — (loss-making) — (loss-making) +36.54% (above 0%: growing) n/m −109.05% (below 0%: shrinking) 98.84% (349.77%) Compare
AVBP ArriVent BioPharma, Inc. $603.0M — (loss-making) — — n/m −51.51% (below 0%: shrinking) — 0.00% Compare
Median of peers $611.7M — — +36.54% — −38.55% 89.95% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 11 May 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 3.36m 7.66m 125.29
2024 1.62m (506.08k) 20.20
2023 2.44m 978.12k 62.27

Ownership

Directors and executive officers, together less than 1%
Entities affiliated with Baker Bros. Advisors 9.99%
Entities affiliated with Suvretta 9.99%
Entities affiliated with MPM BioImpact 6.89%
Entities affiliated with Janus 6.35%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

DBV Technologies S.A. (DBVT) Latest News

29 Oct

Impact 4 · · Investing.com
Impact 4 · · The Motley Fool transcript

28 Oct

Impact 4 · · MarketBeat
Impact 4 · · GlobeNewswire

27 Oct

Impact 3 · · GlobeNewswire

22 Oct

Impact 3 · · MT Newswires

29 Sep

Impact 4 · · GlobeNewswire

17 Jul

Impact 3 ·

16 Jul

Impact 3 · · MarketBeat
Impact 3 ·

29 Jun

Impact 4 ·

17 Jun

Impact 4 ·

8 Jun

Impact 3 · · GlobeNewswire

2 Jun

Impact 4 · · GlobeNewswire

30 Apr

Impact 3 · · GlobeNewswire

14 Apr

Impact 3 · · Zacks
Impact 3 · · Zacks

26 Mar

Impact 4 · · GlobeNewswire

24 Mar

Impact 3 · · GlobeNewswire

15 Mar

Impact 4 · · MarketBeat

7 Mar

Impact 4 · · Simply Wall St.

28 Feb

Impact 4 · · GlobeNewswire

13 Feb

Impact 4 · · MarketBeat

12 Feb

Impact 3 · · Simply Wall St.CoinMarketCapReuters VideosdecryptThe Block

10 Feb

Impact 4 · · GlobeNewswire

18 Jan

Impact 4 · · Simply Wall St.Simply Wall St.

16 Jan

Impact 4 · · GlobeNewswire

21 Dec

Impact 4 · · Insider Monkey

20 Dec

Impact 4 · · Simply Wall St.

18 Dec

Impact 4 · · Simply Wall St.MT NewswiresSimply Wall St.Clinical Trials ArenaSimply Wall St.Simply Wall St.Simply Wall St.
stockrow.com/DBVT · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com